Clinical Trial Update: NEPC Study: An Exploratory Safety and Efficacy Study With PSMA, SSTR2 and GRPR Targeted Radioligand Therapy in Metastatic Neuroendocrine Prostate Cancer. [Phase 1]

View source ↗

Summary

This phase 1 exploratory study evaluates the safety and potential efficacy of a PSMA, SSTR2, and GRPR-targeted radioligand therapy in metastatic neuroendocrine …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroendocrine Prostate Cancer

Drugs mentioned

• PSMA/SSTR2/GRPR-targeted radioligand therapy

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Metastatic Neuroendocrine Prostate Cancer | Phase 1 | Status: ACTIVE_NOT_RECRUITING